"Glucagon"

FSRH Statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception FSRH statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception (Feb 2025) FSRH Skip to main content Login * Register * Contact us * Basket Toggle searchSearch FSRH websiteToggle navigationSearch FSRH website {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]##

Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Return to Article DetailsFormulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Glucagon (Ogluo) - severe hypoglycaemia Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/36/2021 EMEA/H/C/005391 Ogluo (glucagon) An overview of Ogluo and why it is authorised in the EU What is Ogluo and what is it used for? Ogluo is a medicine for treating severe hypoglycaemia (very low levels of glucose in the blood) in patients with diabetes who are at least 2 years old. Hypoglycaemia can occur when diabetes medicines to reduce blood glucose cause glucose

Intranasal Glucagon for the Treatment of Hypoglycemia Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Intranasal Glucagon for the Treatment of HypoglycemiaCopied to clipboardIntranasal Glucagon for the Treatment of Hypoglycemia( Last Updated : June 24, 2022)Project Status:CompletedProject Line:Health Technology ReviewProject Sub Line:Summary with Critical AppraisalProject Number:RC1435-000DetailsQuestionWhat is the clinical effectiveness of IN glucagon versus placebo or no treatment for the treatment of hypoglycemia in people who receive treatment with insulin?What is the clinical effectiveness of IN glucagon versus alternative

Utilization of Glucagon-Like Peptide-1 Receptor Agonists Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Utilization of Glucagon-Like Peptide-1 Receptor AgonistsCopied to clipboardUtilization of Glucagon-Like Peptide-1 Receptor Agonists( Last Updated : September 1, 2022)Project Line:Health Technology ReviewProject Sub Line:Technology ReviewProject Number:HC0042-000Effective finish date:August 31, 2022DetailsA number of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially approved for the treatment of type 2 diabetes mellitus (T2DM), are now indicated for conditions outside of T2DM (e.g., weight management). Currently

glucagon (Baqsimi) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu * Home * COVID-19Specific areasCOVID-19 vaccinesEnd

Prescriptions and Reimbursement of Glucagon Products for Severe Hypoglycemia in Medicaid. This study examines trends in prescribing and reimbursement for glucagon products in Medicaid before and after the introduction of these newer products.

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential antidepressant effects, population studies yield inconsistent results. To compare the risk for depression in older adults with type 2 diabetes (T2D) initiating treatment with GLP

Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP

Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial Glepaglutide is a long-acting GLP-2 analog developed to improve intestinal absorption in short bowel syndrome (SBS) patients. We conducted a trial to establish efficacy and safety of glepaglutide in reducing parenteral support (PS

Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in early-phase studies. We conducted a phase 2a, single-centre, randomized, placebo

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Survodutide is a glucagon/glucagon-like peptide-1 receptor dual agonist in development for treatment of metabolic dysfunction-associated steatohepatitis (MASH). We investigated survodutide in people with cirrhosis. This multinational, non-randomized, open-label : NCT05296733. Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist in development for treatment of metabolic dysfunction-associated steatohepatitis (MASH), which causes cirrhosis in ∼20% of cases. This trial delineates the pharmacokinetic and safety profile of survodutide in people with compensated or decompensated cirrhosis, and revealed associated reductions in liver fat content

Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial. To determine whether a continuous infusion of a glucagon-like peptide receptor (GLP-1R)/glucagon receptor (GCGR) co-agonist, G3215 is safe and well tolerated in adults with overweight or obesity. A phase 1 randomized, double

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape . The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes. The multiple cardiometabolic benefits include improving glycemic control, lipid profiles, blood

Targeting central pathway of Glucose-Dependent Insulinotropic Polypeptide, Glucagon and Glucagon-like Peptide-1 for metabolic regulation in obesity and type 2 diabetes. Obesity and type 2 diabetes are significant public health challenges that greatly impact global well-being. The development of effective therapeutic strategies has become more and more concentrated on the central nervous system and metabolic regulation. The primary pharmaceutical interventions for the treatment of obesity and uncontrolled hyperglycemia are now generally considered to be incretin-based anti-diabetic treatments, particularly glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists. This is a result of their substantial influence on the central nervous system and the consequent effects

A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Cotadutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that may improve kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). In this phase 2b study, patients

GVS assessment of glucagon nasal powder (Baqsimi) for the treatment of severe hypoglycaemia GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia | Report | National Health Care Institute Go to content You are here: Home Publications GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia Search within English part of National Health Care Institute Search GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemiaThe National Health Care Institute has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia in adults, adolescents and children aged 4 and over with diabetes mellitus can be included in the Medication Reimbursement System

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study. A major concern has recently emerged about a potential link between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and increased risk for suicidal ideation and behaviors based on International Classification of Diseases codes

Influence of postruminal casein infusion and exogenous glucagon-like peptide 2 administration on the jejunal mucosal transcriptome in cattle.